Expert Ratings for Aclaris Therapeutics
Portfolio Pulse from Benzinga Insights
Aclaris Therapeutics (NASDAQ:ACRS) has received positive analyst ratings in the last quarter, with 7 bullish and 3 somewhat bullish ratings. The company has an average 12-month price target of $35.29, which has increased by 120.56% over the past month.
October 09, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aclaris Therapeutics has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up.
Analyst ratings are a significant factor that investors consider when making investment decisions. The positive ratings for Aclaris Therapeutics indicate a positive outlook for the company, which could lead to increased investor interest and a potential increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100